rs689466 — PTGS2 A-1195G

PTGS2 A-1195G — When COX-2's Off Switch Is Stuck On

COX-2¹¹ COX-2
Cyclooxygenase-2, encoded by PTGS2, is the inducible isoform of prostaglandin synthase that produces prostaglandins in response to inflammation, injury, and immune signals — distinct from the constitutive COX-1 isoform, which protects the gastric lining is the enzyme that makes prostaglandins — the molecular messengers that drive fever, pain, and the redness and swelling of inflammation. It is also the primary target of NSAIDs including aspirin, ibuprofen, and the now-restricted COX-2 selective inhibitors (coxibs). The rs689466 variant, located 1,195 bases upstream of the PTGS2 transcription start site, sits in the promoter region that controls how much COX-2 protein your cells make. The G allele (reported as C on the genomic plus strand) is associated with reduced COX-2 inducibility — a counterintuitive situation where lower inflammation capacity creates, not prevents, inflammatory disease risk.

The Mechanism

The PTGS2 promoter contains several regulatory elements including NF-kB binding sites, CRE (cAMP response element), and E-box sequences. The A-1195G substitution²² A-1195G substitution
This notation uses coding-strand orientation; PTGS2 is on the minus strand, so the genomic plus-strand alleles are T (reference) and C (variant). All genotype labels below use plus-strand notation as reported by genome files falls within a region that influences transcriptional responsiveness. The G/C variant allele appears to reduce the promoter's ability to drive robust COX-2 expression in response to inflammatory stimuli. This creates a paradox: reduced COX-2 means impaired prostaglandin production in the gut mucosa, where prostaglandins normally support epithelial barrier integrity, mucosal repair, and immune tolerance to luminal antigens. A gut that cannot mount an adequate COX-2 response is paradoxically more susceptible to chronic inflammatory disease — the same mechanism thought to explain why long-term NSAID use (which suppresses COX-2) increases IBD flares and colonic permeability in some patients.

The Evidence

The strongest human evidence comes from a Scottish-Danish case-control study by Andersen et al.³³ Andersen et al.
Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study. Inflamm Bowel Dis, 2011 involving 732 Crohn's disease cases, 973 ulcerative colitis cases, and 1,157 healthy controls. Carriers of the A-1195G variant allele had significantly increased UC risk (OR 1.25, 95% CI 1.02–1.54, P=0.03). The effect was amplified in never-smokers (OR 1.47 for IBD, OR 1.37 overall), and the variant was associated with earlier UC onset (before age 40) and more extensive colitis presentation. No significant association with Crohn's disease was found, suggesting the mechanism is UC-specific — consistent with COX-2's role in colonic epithelial barrier maintenance.

For colorectal cancer, the picture is more complex and requires careful interpretation. A meta-analysis of 16 studies⁴⁴ meta-analysis of 16 studies
Zhang et al. World J Surg Oncol, 2020; 8,998 cases and 11,917 controls found no overall association between rs689466 and CRC risk in the full multi-ethnic population, but a positive association emerged in Caucasians specifically. Critically, the risk is highly dependent on gene-environment interactions: Pereira et al.⁵⁵ Pereira et al.
Genetic variability in key genes in prostaglandin E2 pathway and colorectal cancer. PLoS One, 2014 found that CC homozygotes who were ever-smokers had approximately 6-fold increased CRC susceptibility (OR ~6, 95% CI 1.49–22.42, P=0.011), while non-smokers showed no significant risk elevation. An independent study Andersen et al.⁶⁶ Andersen et al.
Interactions between diet, lifestyle and gene polymorphisms in colorectal cancer. PLoS One, 2013 confirmed interactions with meat intake, fiber, and smoking. A third paper found variant allele carriers had OR 3.23 (95% CI 1.52–6.86)⁷⁷ OR 3.23 (95% CI 1.52–6.86)
Pereira et al. Clin Transl Gastroenterol, 2016 for colorectal adenoma development — the precursor lesion to most CRCs.

One contradictory study Vogel et al.⁸⁸ Vogel et al.
Intestinal PTGS2 mRNA levels and colorectal carcinogenesis. PLoS One, 2014 reported reduced CRC risk in variant allele carriers (OR 0.52, 95% CI 0.28–0.99), highlighting that the direction of effect may differ by tissue context, disease stage, and patient selection. Overall evidence for colorectal cancer risk is moderate and context-dependent.

Practical Implications

For CT and CC genotype carriers, the most actionable implication is colorectal screening and smoking avoidance. The gene-smoking interaction for colorectal cancer is the strongest documented risk amplifier: smoking while carrying the CC genotype generates disproportionate CRC susceptibility beyond the additive risks. Standard colorectal screening protocols (colonoscopy from age 45) remain the primary risk reduction tool. For those with a personal or family history of IBD, awareness that this variant is associated with ulcerative colitis risk and more extensive disease presentation is clinically relevant. COX-2 inhibiting NSAIDs (ibuprofen, aspirin, naproxen, celecoxib) blunt an already-reduced COX-2 pathway — carriers with IBD should discuss NSAID use with a gastroenterologist, as long-term NSAID use may worsen mucosal barrier function in those with low baseline COX-2 activity.

Interactions

The PTGS2 promoter region harbors a second functional polymorphism, rs20417 (COX-2 -765G>C), which has also been associated with IBD and colorectal cancer risk. These two promoter variants are in partial linkage disequilibrium in some populations and may act cooperatively to reduce PTGS2 promoter activity — a compound effect worth investigating in multi-variant models. Another PTGS2 3'UTR variant, rs5275 (T8473C), has been studied in relation to CRC with NSAID interaction; carriers of both rs689466 and rs5275 variant alleles may have altered total COX-2 regulation affecting NSAID response.